sector medic suppli devic
 hard argu result rais
pt
messag full result pre-announce top line
even favor expect incom statement ebita margin top
consensu impress revenu detail also encourag new
growth driver japan rp track ahead expect recent
strength stock like make hard investor get arm around valuat
continu believ uniqu fundament justifi upsid
rais price target reiter buy rate
worth get quarter let spend minut stock
strong outperform thu far vs
result share trade rarifi air valuat standpoint nearli
ntm sale forecast well current multipl high-growth peer
argu sinc first launch coverag month ago think uniqu
combin near-term revenu growth long-term address market opportun
limit threat competit outstand profit clean balanc sheet
make difficult valu tradit metric believ dcf methodolog better
account factor base view reason conserv
assumpt discount rate termin growth rate see current valuat
justifi impact tax reform point benefit continu margin
out-performance om particular serv boost stock impli valu
framework reflect price target increas
surpris see share take breather recent run convict
long-term stori remain unchang
turn back quarter impella turn anoth strong perform driven
grow momentum shock domest impella sale rose
consensu prior compani earli januari pre-announce protect pci
volum grew quarter growth within shock indic came
robust total number patient treat impella rose nearli
expect continu quarter-to-quart volatil impella two main
indic go forward see significantli under-penetrated believ overal
pump volum better indic trajectori grow momentum shock
particularli encourag yet
see real benefit nation csi initi kick three month ago tct
best practic treatment challeng patient becom wide
adopt expect impella penetr popul ramp meanwhil impella
rp roll-out track ahead expect wake product septemb
pma approv train new site rp bring instal base
hospit estim revenu contribut product
tripl yoy albeit small base
impella continu momentum intern well japan set add
anoth signific growth driver ou impella revenu increas
ahead consensu factor currenc modest assum
asp eros estim overal intern pump volum rose germani
continu main engin success sale rise yoy
meanwhil record japanes revenu first quarter post launch
alreadi eclips manag guidanc full year sale contribut
countri expect launch proceed measur pace abiom
work ensur optim clinic outcom continu see japan signific new
growth driver given scale opportun cultur avers open heart
procedur continu page
page analyst certif import disclosur
top line well contain oper expens drove impress leverag
abiom gross margin came yoy
consensu sg spend rose sale street
meanwhil expens grew yoy shi
consensu sale combin drove oper margin
impress vs better street estim see
strong profit key differenti vs high-growth med-tech name
despit primari focu top-lin growth believ compani well posit
drive margin improv go forward manag expect
oper margin come origin guidanc start
year repres nearli improv also
one biggest beneficiari tax reform med-tech sector manag
estim new law shave point effect rate start
line sight beyond reiter buy model call
ep total revenu compar
prior forecast respect long-term continu believ
long growth runway ahead penetr exist market
opportun estim roughli worth note
includ contribut stemi increment opportun could begin
come focu next month enrol dtu feasibl trial
track complet octob forecast world-wide impella sale rise nearli
compound-annual-growth-rate model call oper margin expand
period compani sector realist aspir
kind outlook valuat admittedli leav littl margin error
level believ manag manag street expect execut well
enough continu walk tightrop
page analyst certif import disclosur
leader field mechan circulatori support dedic enabl
safer treatment high-risk patient cardiovascular diseas recov injur
heart muscl estim patient receiv one compani famili
impella heart pump year yet believ scratch surfac
impella long-term potenti estim market opportun includ
stemi see long runway growth level compani match
impella smallest heart pump world design provid temporari
hemodynam support patient undergo high-risk procedur whose cardiac
function compromis sinc impella first receiv approv
impella famili pump use support peopl
alon revenu grow compound-annual-growth-rate period go forward
expect ramp penetr protect pci opportun
penetr cardiogen shock opportun penetr indic
drive continu strong growth compani still earli inning
capit intern opportun impella well recent guidelin
chang germani entri japanes market provid ampl momentum
go forward model call grow total revenu compound-annual-growth-rate
combin strong margin clean balanc sheet limit competit
view arguabl best growth stori med-tech
share trade ntm revenu estim signific premium
high-growth peer believ uniqu combin top line growth
potenti compound-annual-growth-rate profit gm om
make compani difficult valu base tradit metric result employ
discount cash flow methodolog deriv price target assum
wacc previous termin growth rate calcul
year forward npv per share previous use discount rate
compani true cost capit closer take account uncertainti
forward project product approv timelin etc follow recent posit
approv strong perform base busi believ smaller risk
adjust appropri new target equat multipl previous
forward ntm sale estim signific potenti upsid target
current level assign buy rate
downsid risk rate price target includ potenti impella adopt
fall short and/or street forecast pipelin setback clinic failur
weaken outlook faster-than-expect progress potenti impella
competitor premium valuat leav littl margin error view
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
servic
revenu geographi
 unit
 unit indic
compani report guggenheim secur llc estim
page analyst certif import disclosur
